CRISPR Therapeutics AG (CRSP) stock analysis

In our weekly check, CRISPR Therapeutics AG is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12.

About CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Healthcare company (Biotechnology) based in Switzerland, listed on NASDAQ as CRSP.

What our checks show for CRSP

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-11

Similar companies

RLAY · XENE · TARS · AMLX · TNGX · DFTX

Questions

What grade does CRISPR Therapeutics AG (CRSP) have?

In our weekly check, CRISPR Therapeutics AG is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of CRSP stock?

This week's biggest flags for CRISPR Therapeutics AG: High debt, Margins falling, Gross margin falling. In total 15 of 21 checks show a warning or a red flag.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Healthcare company (Biotechnology) based in Switzerland, listed on NASDAQ as CRSP.

When does CRISPR Therapeutics AG report earnings next?

The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis